Tucker Ellis attorney Ronie Schmelz discusses preemption language in the discussion draft from New Jersey congressmen Frank Pallone and Leonard Lance, which actually just confirms that state regulations could continue unchecked. The proposal could identify the Personal Care Products Safety Act in the Senate as the compromise between no preemption and the blanket preemption clause in another House draft bill.
Two cosmetics reform proposals in the House represent federal preemption extremes – one threatening to bar states from regulating almost any aspect of the cosmetics sector and the other giving them virtual carte blanche – which could position the Personal Care Products Safety Act in the Senate as the compromise.
Speaking on the discussion draft released Sept. 14 by Reps. Frank Pallone, D-N.J., and Leonard Lance, R-N.J., Tucker Ellis attorney...
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.
Legislator education is key to checking state bills that overreach, says Ross, executive VP of government affairs at the Personal Care Products Council, discussing the rising tide of US state bills aimed at restricting ingredient use.
FDA reminds companies which registered with agency solely to manufacture OTC sanitizers during COVID-19 public health emergency they will be subject to FY2025 OTC monograph user fees if they don’t delist and deregister as monograph drug manufacturers by 12 a.m. on 31 December.
With monographs@FDA portal down, agency moves to NextGen and extends comment period through 27 September for first OTC monograph change it proposed using its overhauled program other than 32 monographs finalizations required in 2020 legislation authorizing overhaul.
OTC sales edged up at Italy's Recordati in the first half of 2024 as higher demand for GI products and supplements offset a weaker cold & flu season.
P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.
